Evidence map›Paper›PMID 41467459›Full record

ArticlePathology international2026

High Immunohistochemical Expression of SETD5 as a Candidate Pathological Factor for Dedifferentiation and Prognosis in Liposarcoma.

Makoto Abe, Naoto Kubota, Ken Yamazaki, Eisuke Miura, Kaoru Hirabayashi, Masatsugu Ishii, Hirofumi Shirakawa, Kazutaka Kikuta, Yudai Murayama, Rumi Nakagawa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Integrative Analysis UncoversCurrent issues in molecular biology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Makoto AbeDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.ORCID https://orcid.org/0009-0000-3674-2151
Naoto KubotaDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.ORCID https://orcid.org/0000-0002-1849-5078
Ken YamazakiDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Eisuke MiuraDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Kaoru HirabayashiDepartment of Diagnostic Pathology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Masatsugu IshiiDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Hirofumi ShirakawaDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Kazutaka KikutaDepartment of Musculoskeletal Oncology and Orthopedic Surgery, Tochigi Cancer Center, Yonan, Utsunomiya, Tochigi, Japan.
Yudai MurayamaDepartment of Musculoskeletal Oncology and Orthopedic Surgery, Tochigi Cancer Center, Yonan, Utsunomiya, Tochigi, Japan.
Rumi NakagawaDepartment of Musculoskeletal Oncology and Orthopedic Surgery, Tochigi Cancer Center, Yonan, Utsunomiya, Tochigi, Japan.
Hidenori OjimaDivision of Molecular Pathology, Research Institute, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.ORCID https://orcid.org/0000-0001-9154-246X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SET domain containing 5 (SETD5), a chromatin regulator involved in adipocytic differentiation, has been identified in various cancers, but its immunohistochemical expression and prognostic significance in liposarcoma remain unclear. This study examined the immunohistochemical expression and prognostic significance of SETD5 in liposarcomas. SETD5 expression was analyzed in 100 adipocytic tumors using immunohistochemistry; these 100 tumors consisted of 24 dedifferentiated liposarcomas (DDLPS), 24 atypical lipomatous tumors/well differentiated liposarcomas (WDLPS), 12 myxoid liposarcomas, 5 pleomorphic liposarcomas, and 35 benign adipocytic tumors. SETD5 expression was assessed using the immunoreactivity score and its prognostic significance was investigated. SETD5 expression was absent in normal adipose tissue and minimal in lipomas. SETD5 expression was significantly higher in WDLPS than in lipomas (p = 0.01). Moreover, SETD5 expression was markedly elevated in the dedifferentiated component of DDLPS compared to the well-differentiated component (p < 0.001). Pleomorphic liposarcoma showed the highest SETD5 expression levels. In DDLPS, high SETD5 expression in the dedifferentiated component correlated with worse overall survival (p < 0.001) but was not correlated with disease-free survival (p = 0.086). Immunohistochemical expression of SETD5 significantly correlates with prognosis in DDLPS and may serve as a candidate pathological factor for dedifferentiation and prognosis.

Indexed as

Biomarkers, TumorHistone-Lysine N-MethyltransferaseLiposarcomaAdultAgedAged, 80 and overCell DedifferentiationFemaleHumansImmunohistochemistryMaleMiddle AgedPrognosisBiomarkers, TumorHistone-Lysine N-MethyltransferaseKMT5A protein, humanDedifferentiated liposarcomaImmunohistochemistryLiposarcomaPrognostic markerSET Domain Containing 5 (SETD5)

Identifiers

PMID41467459
PMCPMC12835964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.